Bifunctional HDAC Therapeutics: One Drug to Rule Them All?

Histone deacetylase (HDAC) enzymes play crucial roles in epigenetic gene expression and are an attractive therapeutic target. Five HDAC inhibitors have been approved for cancer treatment to date, however, clinical applications have been limited due to poor single-agent drug efficacy and side effects...

Descripción completa

Detalles Bibliográficos
Autores principales: Smalley, Joshua P., Cowley, Shaun M., Hodgkinson, James T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7583022/
https://www.ncbi.nlm.nih.gov/pubmed/32987782
http://dx.doi.org/10.3390/molecules25194394

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7583022/
https://www.ncbi.nlm.nih.gov/pubmed/32987782
http://dx.doi.org/10.3390/molecules25194394

Ejemplares similares